Candel Therapeutics Stock

candeltx.comBioTechFunding to Date: $67.6MM

Developer of cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.

Register for Details

For more details on financing and valuation for Candel Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Candel Therapeutics.

Register Today
Register for Details

For more details on financing and valuation for Candel Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Estuardo Aguilar-Cordova Ph.D
Chief Executive Officer, Chairman and Co-Founder
Stephen Rocamboli JD
Chief Business Officer
Brian Guzik Ph.D
Senior Director, Business Development
Daniel Giroux
Vice President, Manufacturing
Laura Aguilar Ph.D
Chief Medical Officer

Board Members

Alan Smith
Christopher Martell
Edward Benz Jr.
Estuardo Aguilar-Cordova Ph.D
Fred Mermelstein Ph.D
Glenn Mattes
Gregory Gailius
Michael Rubin MD
Northpond Ventures
Mitchell Finer Ph.D
Paul Manning
Sean Stalfort
Udi Meirav Ph.D

Other companies like Candel Therapeutics in the BioTech sector

Sector
 
 
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$185MM
Sector
Last Round Est. Valuation
$1.3B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.89B

News

Advantagene, d.b.a. Candel Therapeutics, a company developing proprietary immuno-oncology platforms, closed a $22.5m Series C financing